Anacor Pharmaceuticals, Inc. 4
4 · Anacor Pharmaceuticals, Inc. · Filed Dec 17, 2015
Insider Transaction Report
Form 4
Zane Lee
VP, Clinical Dev & Interim CMO
Transactions
- Sale
Common Stock
2015-12-15$112.06/sh−1,574$176,379→ 41,173 total - Exercise/Conversion
Stock Option (right to buy)
2015-12-15−14,000→ 27,661 totalExercise: $5.59Exp: 2022-03-13→ Common Stock (14,000 underlying) - Sale
Common Stock
2015-12-15$113.14/sh−9,430$1,066,944→ 31,743 total - Sale
Common Stock
2015-12-15$114.99/sh−100$11,499→ 28,747 total - Exercise/Conversion
Common Stock
2015-12-15$5.59/sh+14,000$78,260→ 42,747 total - Sale
Common Stock
2015-12-15$113.79/sh−2,896$329,524→ 28,847 total
Footnotes (6)
- [F1]Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
- [F2]This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.55 to $112.54, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.56 to $113.55, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.56 to $114.055, inclusive.
- [F6]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was January 1, 2012.